Drug of Choice for Empiric Therapy of Peritonitis
For community-acquired intra-abdominal peritonitis of mild-to-moderate severity in adults, the preferred single-agent empiric therapy is ertapenem (1 g IV every 24 hours), while combination therapy with cefazolin, cefuroxime, or ceftriaxone plus metronidazole is equally acceptable. 1
Treatment Algorithm Based on Severity and Origin
Mild-to-Moderate Community-Acquired Peritonitis
Single-agent options:
- Ertapenem 1 g IV every 24 hours (preferred carbapenem for this severity)
- Cefoxitin 2 g IV every 6 hours
- Moxifloxacin 400 mg IV every 24 hours
- Tigecycline 100 mg loading dose, then 50 mg IV every 12 hours
- Ticarcillin-clavulanate 3.1 g IV every 6 hours
Combination therapy options:
- Cefazolin (1-2 g every 8 hours) + metronidazole (500 mg every 8-12 hours)
- Cefuroxime (1.5 g every 8 hours) + metronidazole
- Ceftriaxone (1-2 g every 12-24 hours) + metronidazole
- Ciprofloxacin (400 mg every 12 hours) + metronidazole 1
High-Severity or High-Risk Community-Acquired Peritonitis
For patients with severe physiologic disturbance, advanced age, or immunocompromised state, broader-spectrum coverage is mandatory:
Preferred agents:
- Piperacillin-tazobactam 3.375 g IV every 6 hours (or 4.5 g every 6 hours for severe infection)
- Meropenem 1 g IV every 8 hours
- Imipenem-cilastatin 500 mg every 6 hours or 1 g every 8 hours
- Doripenem 500 mg IV every 8 hours 1
Alternative combination therapy:
- Cefepime (2 g every 8-12 hours) or ceftazidime (2 g every 8 hours) + metronidazole
- Ciprofloxacin or levofloxacin (750 mg every 24 hours) + metronidazole 1
Health Care-Associated Peritonitis
Empiric therapy must be driven by local resistance patterns and requires multidrug regimens with expanded gram-negative coverage:
- Meropenem, imipenem-cilastatin, doripenem, or piperacillin-tazobactam
- Add vancomycin (15-20 mg/kg every 8-12 hours) for MRSA coverage
- Consider adding an aminoglycoside (gentamicin 5-7 mg/kg every 24 hours) or colistin for multidrug-resistant gram-negative organisms 1
Critical Guideline Recommendations
What NOT to Use
Ampicillin-sulbactam is NOT recommended due to high resistance rates among community-acquired E. coli 1
Cefotetan and clindamycin are NOT recommended due to increasing B. fragilis group resistance 1
Aminoglycosides are NOT recommended for routine use in community-acquired infection due to toxicity concerns, though they remain options for health care-associated infections 1
Empiric enterococcal coverage is NOT necessary for community-acquired peritonitis 1
Empiric antifungal therapy is NOT recommended for community-acquired peritonitis 1
Timing Considerations
- Antimicrobial therapy should begin immediately once peritonitis is diagnosed or strongly suspected
- For septic shock patients, antibiotics must be administered as soon as possible
- For non-shock patients, therapy should start in the emergency department
- Maintain satisfactory drug levels during any source control procedure 1
Important Caveats
Fluoroquinolone Resistance
Due to increasing E. coli resistance to fluoroquinolones, review local susceptibility patterns before using ciprofloxacin or levofloxacin-based regimens 1. This is particularly important as one systematic review showed better clinical cure with ciprofloxacin plus metronidazole compared to β-lactams (OR 1.69), but this may not hold true in areas with high fluoroquinolone resistance 2.
Biliary Tract Infections
For acute cholecystitis of mild-to-moderate severity, narrower-spectrum agents are appropriate: cefazolin, cefuroxime, or ceftriaxone alone. However, severe cholecystitis or cholangitis following bilioenteric anastomosis requires the broader regimens listed above for high-severity peritonitis 1.
Therapy Duration and De-escalation
Once culture and susceptibility results are available, broad-spectrum therapy should be narrowed to reduce unnecessary antibiotic exposure and minimize resistance development 1. Lower-risk patients with satisfactory clinical response do not require therapy changes even if unsuspected pathogens are reported 1.